Mechanistically, dual inhibition of XIAP and SHP2 by embelin lessens the proliferation and metastasis, activates senescence and endogenous apoptosis, inhibits cancer‐related RAS/mitogen‐activated protein kinase (MAPK), phosphoinositide‐3‐kinase (PI3K)/AKT, Janus kinase/signal transducers and activators of transcription (JAK/STAT), wingless‐related integration site (Wnt), and nuclear factor kappa B (NF‐κB) signaling pathways, and overcomes compensatory feedback in the MAPK signals through the modulation of mitogen‐inducible gene‐6 (MIG‐6) and SPROUTY2 (SPRY2). The gene discussed is SPRY2; the disease is cancer.